Navigation Links
First of many Neuro-Biotech's licensed products, "SymPath(R) blood test"
Date:10/4/2010

BASEL, Switzerland, Oct. 4 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) Pursuant to the company's press release issued the 30th of September 2010, the following is a brief review and explanation of the earlier statements concerning the first of many Neuro-Biotech's licensed products, "SymPath(R) blood test".

For a better understanding, an "in vitro" blood test is described as, a non evasive test, whereas the testing, as in the case of SymPath(R), is performed on a small amount of the patient's blood. To date the SymPath(R) blood test has been tested on several thousand of patients whose results illustrate a success rate accuracy of 98.8%. The testing audits have been rigorously documented and have met every industry standard.

SymPath(R) is an indispensable tool with unprecedented results. Medical practitioners have long been waiting for a similar test to accurately and quantifiably diagnose those symptoms amongst patients as, depression and stress related disorders. What does this mean for physicians?

Firstly, SymPath(R) assists the medical practitioner in diagnosing patients, based on quantitative measurement, as precise as current cholesterol tests. SymPath(R) allows the medical practitioner to determine with accuracy the severity level of the patient's anxiety or depressive state. The medical practitioner will now be able to state, based on an objective quantified measure, using this test, rather than subjectively determining the diagnosis, as is currently performed.

Furthermore SymPath(R) will eliminate the costly and highly inefficient trial and errors currently performed by physicians in prescribing their recommended remedy, which can waste time and further cause harm for both patients and physicians. For instance, patients suffering from depression or stress related disorders will now properly diagnosed immediately following the testing through Neuro-Biotech's SymPath(R) test.

No more g
'/>"/>

SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
(Date:7/10/2014)...   Ventana Medical Systems, Inc.  (Ventana), a member ... into an agreement with Merck KGaA, Darmstadt, ... the United States and ... biopharmaceutical division on the development and commercialization of a ... proprietary diagnostic assays. In alignment with Merck KGaA,s strategic ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Specialty Silicone Fabricators (SSF), a leading global ... inaugurated its state-of-the-art 102,000 square-foot facility today in ... facility joins all Paso Robles departments, operations and ... Tustin, Calif. and Elk Rapids, Mich. The new ...
... Ohio, May 29, 2012  Cardinal Health Specialty Solutions ... technology system that makes it easier for payors ... that improve the quality and cost of caring ... rheumatoid arthritis. One of Cardinal Health ...
Cached Medicine Technology:Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles 2Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions 2Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions 3
(Date:7/12/2014)... (PRWEB) July 12, 2014 Demand Response ... with considerable benefits in reducing the imbalance between energy ... grid appliances have been rolled out (due to increasing ... Infrastructure (AMI). This helps in controlling residential appliances and ... growing in the North American region, and with government ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... 2014 With prom shopping reaching its ... retailer, is ready to showcase its new and trendy ... of evening dresses in its online shop. Additionally, it ... for these elegant gowns. According to the company’s sales ... July 26, 2014. , He says, “Now, worldwide ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... Va. (April 13, 2009) While the number of ... registry still only includes 38 percent of licensed drivers, according ... year. Yet, according to a new survey of Americans, ... even if their family disagrees. , "The number of ...
... Rx, Inc., the,pioneering force in measuring the impact of ... physicians, announces that Mark,Degatano has joined the company as ... a newly-created position that expands and,strengthens Impact Rx,s business ... his new role Degatano will lead programs at the ...
... ... April 13, 2009 -- Accept an illicit injection and the result ... Coalition for Injectable Safety. The recent death of a Bronx, NY ... her thighs and buttocks is an unfortunate and repeating pattern of incidents ...
... FARMINGDALE, N.Y., April 13 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has entered into a new, three year, ... Avanco Sistemas Medicos, based in Barcarena, Portugal, for the ...
... wide today as it was in the early ,90s, study ... with lung cancer are less likely than white patients to ... Disparities in lung cancer treatments were as large in 2002 ... there have been efforts to decrease those inequalities in treatment, ...
... As all eyes turn to the health reform debate in ... of California - will urge that "everything be on the ... D.C. Mr. Bodaken will participate in a keynote panel kicking ... that begins with an address by Dora Hughes, counselor to the ...
Cached Medicine News:Health News:While majority of Americans express interest in organ and tissue donation, few register 2Health News:Impact Rx, Inc. Names Mark Degatano as Vice President, Business Development, Key Client Initiatives 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 3Health News:Consumer Alert: Illegal Silicone Injections Result in Death 4Health News:Misonix Announces New Distribution Agreement for Portugal 2Health News:Misonix Announces New Distribution Agreement for Portugal 3Health News:Blacks Less Likely to Get Optimal Lung Cancer Treatment 2Health News:Blue Shield of California CEO to Speak at World Health Care Congress in Washington D.C. 2
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: